Alloy Therapeutics

Alloy Therapeutics is a biotechnology ecosystem company that drives the future of drug discovery and development through AI-powered platforms and integrated services. Since its founding in 2017, Alloy has collaborated with over 200 partners on various biopharmaceutical modalities, including antibodies, bispecific antibodies, genetic medicines, and cell therapies, resulting in more than 100 licensed therapeutic programs, 22 of which have entered clinical development, including two drugs currently in Phase 3 clinical trials. Building on its drug discovery foundation, Alloy has expanded its capabilities across the entire drug development lifecycle, encompassing pharmacology, preclinical and clinical development services, as well as biologics manufacturing.